Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novel oral polio vaccine type 1
- Development stage
- Phase 2
- Lead developer
- PATH
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Novel oral polio vaccine type 1 (nOPV1) is a live attenuated, genetically engineered oral vaccine developed to protect against poliovirus serotype 1. It is designed to improve genetic stability compared to traditional Sabin-based monovalent OPVs and reduce the risk of circulating vaccine-derived poliovirus (cVDPV) outbreaks. The primary indication is the prevention of paralytic disease caused by wild or circulating vaccine-derived poliovirus type 1. The mechanism of action involves stimulating an immune response against poliovirus by introducing a weakened form of the virus that cannot cause disease in healthy individuals but induces protective immunity[5].
- Other names
- nOPV1nOPV-1nOPV 1novel oral poliomyelitis vaccine type 1
02
Targets
Poliovirus type 1 capsid protein
Beyond the preview
Go deeper on Novel oral polio vaccine type 1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novel oral polio vaccine type 1.